Ledby Chairman You Hongtao, Pharcin Pharma launched its IPO of A shares onShenzhen Stock Exchange on Oct. 20, 2017, realizing its debut in capital market, which raised about 140 million yuan for building up its Phase V Production Base. The Company got the meaningful numbers 002907 as its stockcode.
InMay, 2016, Pharscin Pharma officially started to construct the Phase V Production Base in Rongchang District, Chongqing, China. This new production base is strictly complying with ICH-GMP, and is going to pass cGMP certification for achieving the company’s goal of internationalization.
In Aug. 2015, Pharscin Pharma founded another wholly owned subsidiary, Chongqing Pharscin Pharmacy Retail Chain Co., Ltd., expanding its business to pharmacy retail.
Pharscin Pharma finished its share reform at Aug. 2015 , indicating its start of its IPO project.
The building of Pharscin Biotech was officially in use for the company headquarters and R&D center of Pharscin Pharma in March, 2014. At the same year,Pharscin Pharma passed the verification as Academician Expert Workstation.
In Dec. 2014, Pharscin Pharma scessfully acquired 16 drug for dosage forms of freeze-driedpowder injection which further enriched the freeze-dried powder injection product series.
In Apr. 2012, Pharscin Pharma was awarded “China Famous Brand” title by the State Administration for Industry and Commerce.
In Oct. 2011, Pharscin Pharma was granted “National Key Hi-Tech Enterprise” and became the first company in Chongqing passing the new GMP certification.
In Nov. 2010, PharscinPharma finish constructing its phase III production base adding API synthesis production line, GSP warehouse and logistics system.
Pharscin Pharma extends its business to medical distribution by founding Chongqing Pharscin Medicine Co.,Ltd. in Rongchang, Chongqing at Apr. 2009.
In Nov., 2006, the Chongqing Pharscin Biotech Co., Ltd. is established at ChongqingLiangjiang New District and the Phrascin Pharma Research Institute isestablished at the same year.
Inthe year of 2004, Phascin Pharma finished building its phase II production base and expanded its dosage forms of production facilities to powder injection, smalldose injection，freeze-dried powder， soft capsule，powder， Chinese traditional medicine extraction，among which the soft capsule production linebecame the first case in Chongqing.
The first self-built production base called as “phase I production base” of Pharscin Pharma with its four production lines（including tablets,capsules, granules, and API synthesis）passed the GMP certification of NMPA ( former CFDA) at Feb., 2002.
Pharscin Pharma got its first generic drug approval-Weidimei( Hydrotalcid Tablet) which has become the best-selling domestic Hydrotalcid Tablet after years of marketing promoting. Now the gross sales revenue of Weidimei(HydrotalcidTablet) is more than 100 million yuan annually and still keeps a stable growth rate up to date.
Chongqing Pharscin Pharmaceutical Co., Ltd.（abbreviation：Pharscin Pharma）is established at Rongchang District, Chongqing, China, on Nov.18th, 1996.